GRK6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL174637	0.68	13/20
SCHEMBL175027	0.68	13/20
SCHEMBL175028	0.68	13/20
SCHEMBL174284	0.64	11/20
SCHEMBL174152	0.36	8/20
SCHEMBL174350	0.36	8/20
SCHEMBL174351	0.36	8/20
SCHEMBL187199	0.47	7/20
SCHEMBL174692	0.43	7/20
SCHEMBL175038	0.43	7/20
SCHEMBL175039	0.43	7/20
SCHEMBL174916	0.36	7/20
SCHEMBL720607	0.36	7/20
SCHEMBL720608	0.36	7/20
SCHEMBL689549	0.56	6/20
SCHEMBL174253	0.42	6/20
SCHEMBL174254	0.42	6/20
SCHEMBL174255	0.42	6/20
SCHEMBL255852	0.42	6/20
SCHEMBL187583	0.55	5/20

Clinical trials — most relevant to GRK6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Symbicort ® on GR in Sputum in COPD	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis	PHASE2/PHASE3	UNKNOWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP	PHASE2	COMPLETED
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease	PHASE2	COMPLETED
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Effect of Symbicort on GR Localisation in Asthma	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Genetic Predictors of Lithium Response in Bipolar Disorder	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein	nan	COMPLETED
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome	nan	ACTIVE_NOT_RECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.	nan	NOT_YET_RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRK6 binder may also engage these)

Protein	Name	Similarity
P97711	—	1.000	P97711 →
O70293	—	1.000	O70293 →
P43249	—	0.981	P43249 →
GRK4	G protein-coupled receptor kinase 4	0.980	landscape →
GRK5	G protein-coupled receptor kinase 5	0.976	landscape →
Q62833	—	0.975	Q62833 →
Q8VEB1	—	0.974	Q8VEB1 →
P70507	—	0.973	P70507 →
O70291	—	0.971	O70291 →
Q5XIS9	—	0.969	Q5XIS9 →
PRKD2	Serine/threonine-protein kinase D2	0.962	landscape →
Q3UMW7	—	0.962	Q3UMW7 →
PKN1	Serine/threonine-protein kinase N1	0.962	landscape →
A1A4I4	—	0.960	A1A4I4 →
Q8BZ03	—	0.959	Q8BZ03 →
Q66H84	—	0.959	Q66H84 →
Q3SYZ2	—	0.959	Q3SYZ2 →
O43374	—	0.959	O43374 →
Q9DAK3	—	0.959	Q9DAK3 →
P70268	—	0.958	P70268 →
C9J798	—	0.957	C9J798 →
MAPKAPK3	MAP kinase-activated protein kinase 3	0.956	landscape →
O94844	—	0.955	O94844 →
P28327	—	0.954	P28327 →
Q63433	—	0.954	Q63433 →
O95294	—	0.954	O95294 →
Q91009	—	0.954	Q91009 →
Q9Z268	—	0.953	Q9Z268 →
Q8BY35	—	0.952	Q8BY35 →
Q6NYU2	—	0.951	Q6NYU2 →